Atara Biotherapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Atara Biotherapeutics CEO'su Cokey Nguyen, Sep2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 2.28M olup, şirket hissesi ve opsiyonları dahil olmak üzere 23.7% maaş ve 76.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.33% ine doğrudan sahiptir ve bu hisseler $ 227.99K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.2 yıl ve 5 yıldır.

Anahtar bilgiler

Cokey Nguyen

İcra Kurulu Başkanı

US$2.3m

Toplam tazminat

CEO maaş yüzdesi	23.7%
CEO görev süresi	less than a year
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	1.2yrs
Yönetim Kurulu ortalama görev süresi	5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Cokey Nguyen'un ücretlendirmesi Atara Biotherapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$133m
Jun 30 2024	n/a	n/a	-US$181m
Mar 31 2024	n/a	n/a	-US$233m
Dec 31 2023	US$2m	US$540k	-US$276m

Tazminat ve Piyasa: Cokey 'nin toplam tazminatı ($USD 2.28M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 354.57K ).

Tazminat ve Kazançlar: Cokey şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Cokey Nguyen (51 yo)

less than a year

Görev süresi

US$2,277,691

Tazminat

Dr. Anhco Nguyen, Ph D., also known as Cokey, has been the President, Chief Executive Officer and Director of Atara Biotherapeutics Inc. since September 09, 2024. He served as Chief Scientific Officer at A...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Anhco Nguyen	President	less than a year	US$2.28m	0.33% $ 228.0k
Eric Hyllengren	Executive VP	1.6yrs	Veri yok	0.19% $ 135.4k
Alex Chapman	Vice President of Corporate Communications & Investor Relations	no data	Veri yok	Veri yok
Jill Henrich	Executive VP & Chief Regulatory officer	4.2yrs	Veri yok	0.16% $ 112.3k
Rajani Dinavahi	Senior VP & Chief Medical Officer	less than a year	Veri yok	Veri yok

1.2yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: 0HIY 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Anhco Nguyen	President	less than a year	US$2.28m	0.33% $ 228.0k
William Heiden	Independent Director	9yrs	US$237.23k	0.11% $ 73.7k
Matthew Fust	Independent Director	10.7yrs	US$239.73k	0.036% $ 25.2k
Carol Gallagher	Lead Independent Director	11.8yrs	US$260.23k	0.29% $ 204.9k
Gregory Ciongoli	Independent Director	less than a year	Veri yok	Veri yok
Ameet Mallik	Independent Director	3.3yrs	US$219.52k	0.014% $ 9.9k
Maria Roncarolo	Independent Director	4.5yrs	US$229.73k	0.022% $ 15.3k
Pascal Touchon	Chairman of the Board	5.4yrs	US$4.38m	0.49% $ 343.5k

5.0yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0HIY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5 yıldır).

Atara Biotherapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Insufficient new directors

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Independent Director recently bought US$101k worth of stock

Recent updates

New minor risk - Profitability

Third quarter 2024 earnings released: US$2.94 loss per share (vs US$16.40 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Insufficient new directors

Second quarter 2024 earnings released: US$3.10 loss per share (vs US$16.92 loss in 2Q 2023)

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New major risk - Financial position

New minor risk - Insider selling

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.72 loss in 1Q 2023)

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$2.61 loss per share (vs US$2.24 loss in FY 2022)

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Independent Director recently bought US$101k worth of stock

New minor risk - Market cap size

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.82 loss in 3Q 2022)

New major risk - Negative shareholders equity

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.68 loss per share (vs US$0.18 profit in 2Q 2022)

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

President recently sold US$61k worth of stock

Atara Biotherapeutics, Inc. Announces Executive Changes

Full year 2022 earnings released: US$2.24 loss per share (vs US$3.63 loss in FY 2021)

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022

Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Now 35% undervalued

Atara Biotherapeutics, Inc. Announces Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer

Atara and MSK Expects to Provide A Phase 1 Data Update for Ata2271 in Second Half 2022

Atara Biotherapeutics, Inc. Names Charlene Banard as Chief Technical Officer

Atara Biotherapeutics, Inc. Provides Update on ATA2271 Autologous CAR T Trial

Atara Biotherapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 28, 2022

FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million.

Atara Biotherapeutics, Inc. Lauds the Second High Impact Study This Month Solidifying EBV as the Primary Driver of the Development of MS

Atara Biotherapeutics, Inc. to Complete the Biologics License Application for Patients with EBV+ PTLD in Second Quarter of 2022

Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting

Atara Biotherapeutics, Inc. Announces New Preclinical and Preliminary Clinical Results for ATA2271 at ESMO Immuno-Oncology Congress 2021

Atara Biotherapeutics, Inc. Announces That the Marketing Authorization Application for Tabelecleucel (Tab-Cel®) Has Been Fully Validated by the European Medicines Agency

High number of new directors

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of Tab-Cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Ptld)

High number of new directors

Atara Biotherapeutics Announces Operational Progress on Tabelecleucel (Tab-Cel®) for Post-Transplant Lymphoproliferative Disease (PTLD)

SVP & Chief Commercial Officer recently bought US$500k worth of stock

Atara Biotherapeutics Presents Positive Tab-Cel Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect